Table 1 Characteristics of psoriasis patients in present study
From: Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN
Patient | Age, years | Sex | AoO (duration), years | PASI | Nail involvement | PsA | Scalp involvement | Flexural ininvolvement | Treatment |
|---|---|---|---|---|---|---|---|---|---|
P847 | 19 | M | 18 (0.5) | 12.5 | No | No | Yes | No | No |
P652 | 25 | M | 13 (12) | 18.4 | Yes | No | Yes | Yes | No |
P844 | 27 | M | 18 (9) | 8.8 | No | No | Yes | No | No |
P848 | 29 | M | 26 (3) | 3.7 | No | No | Yes | No | No |
P840 | 49 | M | 15 (34) | 6.0 | No | No | Yes | Yes | Calcipotriol + betamethasone |
P845 | 52 | M | 22 (30) | 14.0 | Yes | No | Yes | Yes | No |
P851 | 60 | M | 56 (4) | 10.8 | No | No | Yes | No | No |
P853 | 28 | F | 28 (0.5) | 23.3 | No | No | Yes | No | No |
P849 | 37 | F | 30 (7) | 4.7 | No | No | No | No | Topical steroid |
P856 | 54 | F | 14 (40) | 7.3 | No | Yes | Yes | Yes | Topical steroid |
P843 | 57 | F | 53 (4) | 12.6 | No | No | No | No | Topical steroid |
P846 | 58 | F | 57 (1) | 15.2 | No | No | Yes | No | Topical steroid |